



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kei Aoki
Serial No. : 10/726,904
Filed : December 2, 2003
Title : Use of the neurotoxic component of a botulinum toxin for treating a apastic muscle

Art Unit : 1654
Examiner : Anish Gupta
Conf. No. : 4172

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

The following correspondence relating to this application is enclosed:

- 1) Information Disclosure Statement Letter (2 pages)
- 2) PTO Form 1449 (7 pages)
- 3) Copies of 116 cited documents
- 4) Please charge Deposit Account No. 06-1050 in the amount of \$180 for the Information Disclosure Statement Fee

Please apply any charges not covered, or any credits, to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 1/24/2008

[Signature]
Angela D. Follett, Ph.D.
Reg. No. 60,365

Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: 714.246-4026
Fax: 714.246-4249

60478932.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 24, 2008
Date of Deposit

[Signature]
Signature

MEREDITH MESCHER
Typed or Printed Name of Person Signing Certificate



Docket 16952CON1CIP3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kei Aoki

Serial No.: 10/726,904

Filed: December 2, 2003

For: Use of the neurotoxic component
of a botulinum toxin for treating a
apastic muscle

Examiner: Anish Gupta

Group Art Unit: 1654

Confirmation No.: 4172

Irvine, California

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants provide with regard to the patent application entitled "Use of the neurotoxic component of a botulinum toxin for treating a apastic muscle" filed herewith one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 24, 2008

Date of Deposit

Signature

Meredith Mescher

Meredith Mescher

Typed or Printed Name of Person Signing Certificate

01/30/2008 AAKHADI 00000014 061050 10726904
01 FC:1806 180.00 DA

Applicants would like to make the Examiner aware of copending U.S. Application Serial Nos. 10/460,898; 10/443,593; 10/976,507; 10/461,829; 10/933,723; 11/675,439; 11/675,450; 11/740,790; 11/740,809; 11/740,823; and 11/752,096. Applicants request that the Examiner review the file histories, including pending claims in the same.


While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

Please charge Deposit Account No. 06-1050 in the amount of \$180 for the Information Disclosure Statement Fee. The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 06-1050.

Date:

1/24/2008

Respectfully submitted,


Angela Follett, Reg No. 60,365

Please direct all inquiries and correspondence to:

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: 714.246-4026
Fax: 714.246-4249